ICH E3 section 12.6 calls for an overall safety evaluation that highlights important events, identifies patients or groups at increased risk, and discusses implications for possible use of the investigational product. This is an overall safety synthesis under ICH E3 12.6, not a duplicate event listing, safety table, or patient narrative.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Use the Safety Conclusions section to synthesize the overall safety evaluation, identify higher-risk patients or groups, and state implications for possible use of the investigational product.
Key details
Core IssueICH E3 section 12.6 calls for an overall safety evaluation that highlights important events, identifies patients or groups at increased risk, and discusses implications for possible use of the investigational product.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is an overall safety synthesis under ICH E3 12.6, not a duplicate event listing, safety table, or patient narrative.
Further guidance
Content
Review the main safety findings with attention to dose changes, concomitant medication, serious adverse events, withdrawals, deaths, and potentially vulnerable or higher-risk groups.
Purpose
Use the Safety Conclusions section to synthesize the overall safety evaluation, identify higher-risk patients or groups, and state implications for possible use of the investigational product.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 Section 9.5 calls for identification of the efficacy and safety variables assessed, the methods and timing of assessments, and the people or procedures responsible for measurements, often with a schedule or flow chart. This section defines variables and assessment methods; it is not the same artifact as the later efficacy or safety result tables.
ICH E3 section 11.4.7 provides a dedicated place for efficacy conclusions after the detailed efficacy analyses and supporting displays. Do not use the conclusion to overrule the detailed analyses or convert exploratory findings into confirmed primary results.
ICH E3 reserves section 14.3 for safety data displays, including adverse-event presentations and listings supporting deaths, serious events, laboratory findings, and other safety analyses. This page covers supporting ICH E3 safety displays and listings; it is distinct from the main Safety Results section and from patient narratives.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
